{"schema":"pith.reference-change-event.v1","doi":"10.1016/s0140-6736(19)32591-7","canonical_url":"https://pith.science/event/10.1016/s0140-6736(19)32591-7","json_url":"https://pith.science/event/10.1016/s0140-6736(19)32591-7.json","not_a_judgment":"This page records that a citing paper's bibliography includes a work with a published notice. It is not a judgment on the citing paper.","primary":{"event_id":469375,"doi":"10.1016/s0140-6736(19)32591-7","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2021-06-10","title":"Department of Error","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","work_arxiv_id":null,"notice_doi":"10.1016/s0140-6736(21)01119-3","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/s0140-6736(19)32591-7","json_href":"/event/10.1016/s0140-6736(19)32591-7.json"},"events":[{"event_id":469375,"doi":"10.1016/s0140-6736(19)32591-7","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2021-06-10","title":"Department of Error","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","work_arxiv_id":null,"notice_doi":"10.1016/s0140-6736(21)01119-3","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/s0140-6736(19)32591-7","json_href":"/event/10.1016/s0140-6736(19)32591-7.json"},{"event_id":422586,"doi":"10.1016/s0140-6736(19)32591-7","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2020-02-21","title":"Department of Error","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","work_arxiv_id":null,"notice_doi":"10.1016/s0140-6736(20)30254-3","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/s0140-6736(19)32591-7","json_href":"/event/10.1016/s0140-6736(19)32591-7.json"},{"event_id":465775,"doi":"10.1016/s0140-6736(19)32591-7","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2020-01-23","title":"Department of Error","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","work_arxiv_id":null,"notice_doi":"10.1016/s0140-6736(20)30116-1","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/s0140-6736(19)32591-7","json_href":"/event/10.1016/s0140-6736(19)32591-7.json"}],"flags":[{"id":8487,"status":"open","status_label":"Open","citing_arxiv_id":"2509.04939","citing_title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","ref_index":25,"evidence_raw":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7","evidence_cleaned":null,"evidence_source_label":"bibliography line","event_type":"correction","event_type_label":"Correction","source_label":"Crossref","event_date":"2021-06-10","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","event_doi":"10.1016/s0140-6736(19)32591-7","flag_href":"/flags/8487","event_href":"/event/10.1016/s0140-6736(19)32591-7","paper_href":"/paper/2509.04939","created_at":"2026-08-05T06:18:38.113482Z","dispute_note":null,"disputed_at":null,"disputed_by":null},{"id":8486,"status":"open","status_label":"Open","citing_arxiv_id":"2509.04939","citing_title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","ref_index":25,"evidence_raw":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7","evidence_cleaned":null,"evidence_source_label":"bibliography line","event_type":"correction","event_type_label":"Correction","source_label":"Crossref","event_date":"2020-01-23","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","event_doi":"10.1016/s0140-6736(19)32591-7","flag_href":"/flags/8486","event_href":"/event/10.1016/s0140-6736(19)32591-7","paper_href":"/paper/2509.04939","created_at":"2026-08-05T06:18:37.366034Z","dispute_note":null,"disputed_at":null,"disputed_by":null},{"id":8483,"status":"open","status_label":"Open","citing_arxiv_id":"2509.04939","citing_title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","ref_index":25,"evidence_raw":"Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7","evidence_cleaned":null,"evidence_source_label":"bibliography line","event_type":"correction","event_type_label":"Correction","source_label":"Crossref","event_date":"2020-02-21","work_title":null,"work_doi":"10.1016/s0140-6736(19)32591-7","event_doi":"10.1016/s0140-6736(19)32591-7","flag_href":"/flags/8483","event_href":"/event/10.1016/s0140-6736(19)32591-7","paper_href":"/paper/2509.04939","created_at":"2026-08-05T06:18:34.440174Z","dispute_note":null,"disputed_at":null,"disputed_by":null}],"flag_count":3,"flags_open":3,"flags_disputed":0,"desk_url":"https://pith.science/flags"}